NCT07023289 - A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease | Biotech Hunter

Enrollment

140

Participants

Timeline

Start Date

August 7, 2025

Primary Completion Date

November 30, 2029

Study Completion Date

November 30, 2029

Conditions

Colorectal Cancer

Interventions

DRUG

Telisotuzumab Adizutecan

Intravenous (IV) Infusion

DRUG

Standard of Care

Standard of care treatment based on investigator's judgement to the active surveillance.

Trial Locations (17)

100

RECRUITING

National Taiwan University Hospital /ID# 273580, Taipei City

404

RECRUITING

China Medical University Hospital /ID# 274644, Taichung

807

RECRUITING

Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 273745, Kaohsiung City

7100

RECRUITING

Vejle Sygehus /ID# 274368, Vejle

11042

RECRUITING

Northwell Health Center for Advanced Medicine /ID# 275331, Lake Success

37203

RECRUITING

SCRI Oncology Partners /ID# 274522, Nashville

55404

RECRUITING

Scri Minnesota Oncology Hematology, P.A. /ID# 275149, Minneapolis

76051

RECRUITING

Texas Oncology-Grapevine /ID# 275155, Grapevine

78705

RECRUITING

Texas Oncology - Central/South Texas /ID# 275154, Austin

97227-1800

RECRUITING

Northwest Cancer Specialists /ID# 275151, Portland

501-1194

RECRUITING

Gifu University Hospital /ID# 274179, Gifu

232-0024

RECRUITING

Yokohama City University Medical Center /ID# 273657, Yokohama

540-0006

RECRUITING

National Hospital Organization Osaka National Hospital /ID# 274306, Osaka

411-8777

RECRUITING

Shizuoka Cancer Center /ID# 275480, Sunto-gun

03080

RECRUITING

Seoul National University Hospital /ID# 274451, Seoul

05505

RECRUITING

Asan Medical Center /ID# 274454, Seoul

06351

RECRUITING

Samsung Medical Center /ID# 274452, Seoul